Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Clinical Obstetrics and Gynecology|January 16, 2013
Cost-effectiveness of cervical cancer preventionKatharine M Esselen, Sarah Feldman
Gynecologic Oncology|February 8, 2021
Crowdsourcing to measure financial toxicity in gynecologic oncologyKatharine M Esselen, Hannah Stack-Dunnbier, Annika Gompers, et al.
Birth (Berkeley, Calif.)|February 22, 2023
Financial toxicity in pregnancy and postpartumAnnika Gompers, Elysia Larson, Katharine M Esselen, et al.
Obstetrics and Gynecology|October 8, 2015
Health Care Disparities in Hysterectomy for Gynecologic Cancers: Data From the 2012 National Inpatient SampleKatharine M Esselen, Allison Vitonis, Jon Einarsson, et al.
Journal of Obstetric, Gynecologic, and Neonatal Nursing : JOGNN|June 1, 2024
Financial Toxicity in Relation to ChildbirthAnnika Gompers, Elysia Larson, Katharine M Esselen, et al.
Journal of Pharmaceutical Policy and Practice|June 6, 2024
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathwayMahnum Shahzad, Huseyin Naci, Katharine M Esselen, et al.
Gynecologic Oncology|June 5, 2012
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapyKatharine M Esselen, Noah Rodriguez, Whitfield Growdon, et al.
Gynecologic Oncology|April 18, 2026
Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancerTina Yi Jin Hsieh, Ting-Tai Yen, Michele R Hacker, et al.
Gynecologic Oncology|February 9, 2023
Financial toxicity: A practical review for gynecologic oncology teams to understand and address patient-level financial burdensMargaret I Liang, Ross Harrison, Emeline M Aviki, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 13, 2025
Comparative analysis of adjuvant treatment outcomes in stage III endometrial cancer: overall survival, recurrence-free survival, site of primary recurrence, and toxicityAlex E Rosenthal, Natalie Posever, Anna Modest, et al.
Pageof 4